Paola Orlandi
Pisa, 56126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients.
Journal: Journal of clinical medicine
Published: June 16, 2026
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.
Journal: Oncology research
Published: September 25, 2025
Digital Microneedles for Multiplexed Transdermal Sensing via Fluorescent QR Codes.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: September 25, 2025
Mathematical analysis of metronomic chemotherapy response in metastatic gastrointestinal cancer: identifying critical parameters from clinical data.
Journal: Scientific reports
Published: August 25, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells.
Journal: Investigational new drugs
Published: July 17, 2025
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: May 07, 2025
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo.
Journal: Journal of clinical medicine
Published: December 16, 2024
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway.
Journal: Scientific reports
Published: November 06, 2024
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.
Journal: Investigational new drugs
Published: October 11, 2024
Metronomic Chemotherapy in Elderly Patients.
Journal: Current oncology reports
Published: February 05, 2024
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.
Journal: Biochemical pharmacology
Published: September 09, 2023
Last Updated: 09/26/2026